



Kevin M. Maloney

Kevin M. Maloney earned a B.S. in chemistry and biochemistry from Stetson University in 2022 and then moved to Cambridge, Massachusetts, where he earned a Ph.D. in organic chemistry from the Massachusetts Institute of Technology in 2007 under the guidance of Professor Rick Danheiser. His graduate research focused on developing novel iminoacetonitrile cycloadditions as a general strategy for natural product synthesis.

In 2007, Kevin moved to New Jersey and began his professional career at Merck. Over the ensuing 18 years, Kevin has developed his experience and expertise over a range of roles in Process Chemistry, Discovery Process Chemistry, and Enabling Technologies, culminating in his current Executive Director position leading the Process Chemistry group. He excels at delivering value to the company and patients alike, spearheading innovation on both the current and future pipeline, and developing the next generation of talent in the organization that will allow Merck to continue to invent for life.

Kevin's success in Process Chemistry is exemplified by his pursuit of breakthrough innovations using enabling technologies in synthetic organic chemistry to develop the simplest, greenest and most cost-effective commercial manufacturing processes for Active Pharmaceutical Ingredients. His teams have employed chemocatalysis, flow chemistry and biocatalysis to develop green and sustainable commercial manufacturing processes for [ceftolozane sulfate](#) (the antibiotic in Zerbaxa™), [gefapixant](#) (an investigational candidate for the treatment of chronic cough), and [islatravir](#) (an investigational candidate for the treatment for HIV). Through Kevin's leadership, a revolutionary advance in nucleoside synthesis for islatravir was developed utilizing an enzymatic cascade process that has changed the way chemists think about making [nucleosides](#). Building on this innovative approach, a green and sustainable three-step process utilizing [a novel biocatalytic cascade](#) was developed for molnupiravir (Lagevrio™).

In addition to his Merck pipeline accomplishments, Kevin has collaborated with his colleague, Dr. Patrick Fier, to establish a research program developing new synthetic methodologies focused on a novel hydroxylation reaction to prepare complex phenols ([Maloney-Fier Hydroxylation](#)) and on transformation of sulfonamides for [late-stage functionalization](#), resulting in five publications.

Kevin is a champion for Green Chemistry and, as the leader of Merck's Green & Sustainable Science Team, has enhanced the organization's leading position in the industry through his advocacy and influence both inside and outside of Merck. He has co-authored 6 successful EPA Green Chemistry Challenge Award nominations and established API sustainability targets for small molecules as part of Merck's corporate sustainability goals. Lastly, he is influential in the science community with more than [45 publications](#), several invited lectures, and was recently awarded the inaugural ACS Division of Organic Chemistry Mid-Career Industrial Investigator Award and the SCI Gordon E. Moore Medal.

Outside of work, Kevin enjoys spending time with his family, playing sports and video games with his son Brady, walking his dogs, and riding his Peloton.